Summary：**BMGL Restores Nasdaq Compliance, Boosting Investor Confidence After Price Struggle** *Singapore,

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**BMGL Restores Nasdaq Compliance, Boosting Investor Confidence After Price Struggle**
*Singapore, July 10, 2026 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL) announced today that it has received formal notification from Nasdaq confirming the company’s return to compliance with the exchange’s minimum bid price rule. The development ends a six‑month period during which BMGL’s share price hovered below the $1.00 threshold, triggering concerns about possible delisting.*

### Introduction
Basel Medical Group, a Singapore‑based developer of minimally invasive surgical devices, disclosed that Nasdaq’s Letter of Determination, dated July 8, 2026, verified that the company’s closing bid price has remained at or above $1.00 for ten consecutive trading days. The notice marks the official end of the non‑compliance period that began after the stock slipped below the mandated level in January 2026.

### Key Developments
The compliance turnaround follows a series of corrective actions undertaken by BMGL’s board and management team. In early 2026, the company instituted a targeted share‑buyback program, repurchasing approximately 4.2 million shares at an average price of $0.92. Simultaneously, BMGL accelerated the commercial rollout of its flagship endoscopic stapler in Europe and secured a $75 million senior loan facility to strengthen liquidity.

Chief Executive Officer Dr. Li Wei commented, “Regaining Nasdaq compliance validates the disciplined execution of our turnaround plan and reassures